Carrie L. Langstraat, MD, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.
Carrie L. Langstraat, MD, a gynecologic oncologist at Mayo Clinic, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.
Lansgtraat highlighted findings from a retrospective study in Ohio. The study was able to demonstrate that patients with endometrial cancers who had para-aortic lymph node involvement in addition to pelvic node involvement had worse survival compared with those who had early pelvic nodal involvement.
According to Langstraat, these data are marginal, but there is a decrease in survival for patients with para-aortic lymph node involvement.
<< View more resources and information regarding gynecologic cancers
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More